secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2026-05-13T21:15:17+00:00
Accession:  0001171843-26-003381
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose Q1 net loss $7.6M, cash $4.1M; Hanmi acquisition delayed, TUS data at EHA
--------------------------------------------------------------------------------

- Net loss of $7.6M ($2.99/share) for Q1 2026 vs $5.5M ($2.61/share) in Q1 2025.
- Cash and restricted cash $4.1M; working capital deficit $5.1M; relies on Hanmi advances to fund operations.
- Hanmi acquisition delayed due to pending Korean regulatory approvals; target close May 2026 at C$2.41/share (28% premium).
- TUS+VEN+AZA triplet data from TUSCANY trial selected for oral presentation at EHA2026 Congress in June.
- Luxeptinib license rights returned to CGI; program winding down.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184326003381/0001171843-26-003381-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184326003381/f8k_051326.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-003381

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer